Form 4: Agilon Health Director Receives Equity Grant Post-Split

Director John William Wulf was granted 2,133 restricted stock units as part of his compensation, following a recent 1-for-25 reverse stock split.

Summary

• John William Wulf, a director at agilon health, inc. (AGL), was granted 2,133 restricted stock units (RSUs) on June 2, 2026.
• The RSUs are scheduled to vest in full on June 2, 2027, contingent upon continued service on the board.
• Following this transaction, Wulf beneficially owns a total of 16,765 shares of common stock.
• The reported ownership figures reflect a 1-for-25 reverse stock split that became effective on March 30, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing. While the equity grant shows director alignment, the context of a massive reverse stock split earlier in the year signals significant historical volatility.

Positives

• Director compensation is aligned with shareholder interests through equity-based grants.
• The director maintains a significant ownership stake of 16,765 shares, demonstrating long-term commitment to the company.

Negatives

• The company executed a substantial 1-for-25 reverse stock split in March 2026, which is typically a response to a significantly depressed share price.

Risks

• The ultimate value of the RSU grant is dependent on the company's stock price performance over the next year.
• Historical downward pressure on the stock price necessitated a reverse split to maintain exchange listing requirements or improve marketability.

Future Outlook

The grant ensures director oversight and alignment through mid-2027. The company's capital structure has been recently adjusted via a reverse split, suggesting a focus on price stabilization and meeting regulatory requirements for continued trading.

Management Comments

• Restricted stock units vest in full on June 2, 2027, subject to continued service as a director.
• The amount of securities beneficially owned reflects the 1 for 25 reverse stock split effective March 30, 2026.

Industry Context

StockSavvy.ai notes that agilon health's decision to issue equity to directors is standard for the healthcare sector, though the recent 1-for-25 reverse split highlights the significant valuation challenges the company has faced compared to more stable peers in the value-based care space.

Comparison to Industry Standards

• The RSU vesting period of one year is consistent with standard board compensation practices at companies like Oak Street Health or CareMax.
• A 1-for-25 reverse split is more aggressive than typical industry adjustments, indicating a more severe historical price decline than many S&P 500 healthcare constituents.

Corporate Governance

Related Party Transactions

• The issuance of 2,133 RSUs to John William Wulf as part of director compensation.

Stakeholder Impact

• Shareholders see continued insider participation in the company's equity.
• The director is incentivized to remain with the company through at least June 2027.

Next Steps

• Vesting of the 2,133 RSUs on June 2, 2027.

Key Dates

Recommendation

This filing represents a routine grant of equity to a director. While it shows insider alignment, it does not provide new material information regarding the company's operational performance or future earnings that would warrant a change in investment thesis, especially following the recent reverse split.

Keywords

agilon health, AGL, Insider Trading, Director Compensation, Restricted Stock Units, Reverse Stock Split, Healthcare Services, SEC Form 4